Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma by Jerome T. Higgs, Joo Hyoung Lee,

Slides:



Advertisements
Similar presentations
Volume 11, Issue 5, Pages (January 2009)
Advertisements

From: Inhibin A Is an Endocrine Stimulator of Bone Mass and Strength
Molecular Therapy - Nucleic Acids
Recovery from hind limb ischemia is less effective in type 2 than in type 1 diabetic mice: Roles of endothelial nitric oxide synthase and endothelial.
Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss by Muhammad Zahoor, Marita Westhrin,
In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression.
by Benjamin J. Frisch, John M. Ashton, Lianping Xing, Michael W
The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice by Hitendra Singh Chand, Xin.
Long-term imatinib therapy promotes bone formation in CML patients
Glycoprotein Nonmelanoma Clone B Regulates the Crosstalk between Macrophages and Mesenchymal Stem Cells toward Wound Repair  Bing Yu, Talib Alboslemy,
by Alexis S. Bailey, Shuguang Jiang, Michael Afentoulis, Christina I
In vivo retroviral gene transfer by direct intrafemoral injection results in correction of the SCID phenotype in Jak3 knock-out animals by Christine S.
Volume 11, Issue 2, Pages (September 2013)
Mesenchymal stem cell–mediated ectopic hematopoiesis alleviates aging-related phenotype in immunocompromised mice by Takayoshi Yamaza, Yasuo Miura, Kentaro.
by Yoshinobu Maeda, Pavan Reddy, Kathleen P
Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.
RANKL Inhibition Blocks Osteolytic Lesions and Reduces Skeletal Tumor Burden in Models of Non–Small-Cell Lung Cancer Bone Metastases  Robert E. Miller,
Mesenchymal Stem Cells (MSCs) Attenuate Cutaneous Sclerodermatous Graft-Versus- Host Disease (Scl-GVHD) through Inhibition of Immune Cell Infiltration.
Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists by Christopher T.
Endovenous Administration of Bone Marrow-Derived Multipotent Mesenchymal Stromal Cells Prevents Renal Failure in Diabetic Mice  Fernando Ezquer, Marcelo.
Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic.
Volume 7, Issue 5, Pages (November 2010)
Parathyroid Hormone Directs Bone Marrow Mesenchymal Cell Fate
Retroviral-mediated expression of recombinant Fancc enhances the repopulating ability of Fancc −/− hematopoietic stem cells and decreases the risk of clonal.
Attenuated MDSC-suppressive activity and metastasis development in IDO-deficient mice is rescued by IL-6. Attenuated MDSC-suppressive activity and metastasis.
TLR5 signaling in murine bone marrow induces hematopoietic progenitor cell proliferation and aids survival from radiation by Benyue Zhang, Damilola Oyewole-Said,
Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone.
by Bindu Varghese, Adam Widman, James Do, Behnaz Taidi, Debra K
Volume 9, Issue 3, Pages (March 2004)
Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis by Catharina Wenk, Anne-Kathrin.
Systemic Therapy of Disseminated Myeloma in Passively Immunized Mice Using Measles Virus-infected Cell Carriers  Chunsheng Liu, Stephen J Russell, Kah-Whye.
Volume 6, Issue 4, Pages (April 2016)
The potential of umbilical cord blood multipotent stem cells for nonhematopoietic tissue and cell regeneration  Carmella van de Ven, Daniel Collins, M.
Volume 24, Issue 5, Pages (November 2013)
Isolation of multipotent mesenchymal stem cells from umbilical cord blood by Oscar K. Lee, Tom K. Kuo, Wei-Ming Chen, Kuan-Der Lee, Shie-Liang Hsieh, and.
Volume 18, Issue 10, Pages (October 2010)
T. Kimura, T. Ozaki, K. Fujita, A. Yamashita, M. Morioka, K. Ozono, N
Volume 19, Issue 1, Pages (January 2011)
Volume 21, Issue 8, Pages (November 2017)
Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice by Rikke Stagaard, Carsten Dan Ley, Kasper Almholt,
Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells by Xiaoli Wang, Cing Siang Hu, Bruce Petersen, Jiajing.
VAY-736 combines effectively with ibrutinib in vivo.
Volume 13, Issue 6, Pages (November 2015)
Recovery from hind limb ischemia is less effective in type 2 than in type 1 diabetic mice: Roles of endothelial nitric oxide synthase and endothelial.
Characterization of Tfrc-mutant mice with microcytic phenotypes
Volume 24, Issue 2, Pages (February 2016)
Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis by Tomohiro Umezu, Satoshi Imanishi, Kenko.
A role for IL-34 in osteolytic disease of multiple myeloma
Volume 26, Issue 1, Pages (January 2018)
Myeloma cell–derived Runx2 promotes myeloma progression in bone
Volume 7, Issue 3, Pages (March 2003)
Epithelial loss of TβRII results in increased Th17 cell development.
Twist1 regulates embryonic hematopoietic differentiation through binding to Myb and Gata2 promoter regions by Kasem Kulkeaw, Tomoko Inoue, Tadafumi Iino,
Volume 4, Issue 3, Pages (March 2015)
Volume 18, Issue 5, Pages (May 2010)
Volume 20, Issue 5, Pages (May 2012)
by Yue Wei, Hong Zheng, Naran Bao, Shan Jiang, Carlos E
Volume 18, Issue 8, Pages (August 2010)
Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma by Ilyas Sahin, Yawara Kawano, Romanos.
Bone marrow transplantation prevents right ventricle disease in the caveolin-1–deficient mouse model of pulmonary hypertension by Kewal Asosingh, Nicholas.
Volume 18, Issue 6, Pages (June 2010)
Recovery from hind limb ischemia is less effective in type 2 than in type 1 diabetic mice: Roles of endothelial nitric oxide synthase and endothelial.
Intratumoral platelet aggregate formation in a murine preclinical glioma model depends on podoplanin expression on tumor cells by Barbara Costa, Tanja.
Molecular Therapy - Oncolytics
Volume 25, Issue 4, Pages (April 2017)
Volume 8, Issue 6, Pages (June 2017)
Fig. 6 Local COX-2 overexpression targeted CD90+ mSSCs to accelerate bone repair. Local COX-2 overexpression targeted CD90+ mSSCs to accelerate bone repair.
IL-17A mediates cutaneous GVHD
Volume 18, Issue 10, Pages (October 2010)
Volume 21, Issue 6, Pages (June 2012)
Presentation transcript:

Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma by Jerome T. Higgs, Joo Hyoung Lee, Hong Wang, Vishnu C. Ramani, Diptiman Chanda, Cherlene Y. Hardy, Ralph D. Sanderson, and Selvarangan Ponnazhagan BloodAdv Volume 1(25):2375-2385 November 28, 2017 © 2017 by The American Society of Hematology

Jerome T. Higgs et al. Blood Adv 2017;1:2375-2385 © 2017 by The American Society of Hematology

Characterization of human MSCs Characterization of human MSCs. hMSCs were isolated from remnants of bone marrow transplant bags and cultured in DMEM with 10% FCS. Upon confluence, the cells were harvested and stained with antihuman CD11b to exclude the population that was positive for this marker. Characterization of human MSCs. hMSCs were isolated from remnants of bone marrow transplant bags and cultured in DMEM with 10% FCS. Upon confluence, the cells were harvested and stained with antihuman CD11b to exclude the population that was positive for this marker. The remaining cells were sorted as positive for CD90, CD73, and CD44, and negative for CD45 (A) and cultured to confluence. The pluripotency of MSCs was determined by adipogenic and osteogenic differentiation assays using ADM and ODM, respectively. Fourteen days later, Oil-Red-O staining was performed for lipid droplets, and Alizarin red staining was performed for calcium deposition. Replicates of cells, grown in ODM, were also subjected to von Kossa staining on day 21 for mineralization. Original magnification ×100 (B). Jerome T. Higgs et al. Blood Adv 2017;1:2375-2385 © 2017 by The American Society of Hematology

Establishment of a mouse myeloma model with skeletal dissemination of tumor and osteolysis. Establishment of a mouse myeloma model with skeletal dissemination of tumor and osteolysis. Two different mouse models were tested for myeloma osteolytic dissemination. Groups of BALB/c mice were challenged with 5 × 105 MPC-11 cells, and SCID mice were challenged with 5 × 105 CAGHep cells via tail vein. Based on constitutive expression of firefly luciferase in both cell lines, mice were monitored by noninvasive imaging to monitor tumor growth within the tibia, femur, and spine. Cohorts of mice from each group were euthanized at the indicated time points, and bones were subjected to histology (A-B; original magnification ×100, hematoxylin and eosin stain) and micro-CT (C). Representative data indicate aggressive tumor growth and skeletal damage in the BALB/c-MPC-11 model by 2 weeks. However, the growth of myeloma cells in the SCID-CAGHep model was significantly delayed, allowing a window of >6 weeks before aggressive bone destruction was noted. Jerome T. Higgs et al. Blood Adv 2017;1:2375-2385 © 2017 by The American Society of Hematology

Noninvasive bioluminescence imaging as a measure of therapeutic potential of OPG variants as compared with WT OPG. Groups of SCID mice were challenged with 5 × 105 CAGHep cells via tail vein followed by noninvasive imaging for establishment of tumor cells around day 14. Noninvasive bioluminescence imaging as a measure of therapeutic potential of OPG variants as compared with WT OPG. Groups of SCID mice were challenged with 5 × 105 CAGHep cells via tail vein followed by noninvasive imaging for establishment of tumor cells around day 14. Cohorts of mice were then left untreated or administered with hMSCs modified to express WT OPG (OPGwt), or OPG variants: OPGY49R/OPGF107A. Tumor growth following therapy was monitored by noninvasive imaging on day 7 (day 21 after tumor challenge), and day 14 (day 28 after tumor challenge) after initiation of therapy. Jerome T. Higgs et al. Blood Adv 2017;1:2375-2385 © 2017 by The American Society of Hematology

Micro-CT and quantitative analysis of tibia and spine following hMSC-OPG therapy. Micro-CT and quantitative analysis of tibia and spine following hMSC-OPG therapy. Four weeks after tumor challenge, a time established as midpoint for the degree of osteolytic damage, cohorts of mice from untreated and indicated treatment groups were euthanized, and tibia (A) and spine (B) were subjected to micro-CT analysis. Data obtained from micro-CT were used in 3D reconstruction images and quantitative analysis of respective bones for connectivity density, trabecular number, and trabecular spacing (*P < .05; **P < .01, compared with untreated mice following tumor challenge). Jerome T. Higgs et al. Blood Adv 2017;1:2375-2385 © 2017 by The American Society of Hematology

Osteoclast staining in tibia and spine following hMSC-OPG therapy. Osteoclast staining in tibia and spine following hMSC-OPG therapy. Bone tissues were harvested from mice in control and indicated treatment groups 28 days following tumor challenge. The bones were decalcified, and 5-µM sections were made. The slides were stained with TRAP stain on both tibia and spine for osteoclast activity within the bone microenvironment. Original magnification ×100. Jerome T. Higgs et al. Blood Adv 2017;1:2375-2385 © 2017 by The American Society of Hematology

ELISA for OPG levels. ELISA for OPG levels. Forty-eight hours after transduction of hMSCs with AAV-OPGwt or AAV-OPGY49R or AAV-OPGF107A culture, supernatants were analyzed by ELISA for OPG levels using a commercial kit (A). OPG levels were also quantitated in mouse serum following therapy. Blood samples were obtained from untreated and hMSC-OPG–treated mice both prior to initiating hMSC therapy and 14 days after the treatment and similarly analyzed by ELISA for OPG levels (B). Data presented are mean ± standard error from triplicate experiments (*P < .05; **P < .01). Jerome T. Higgs et al. Blood Adv 2017;1:2375-2385 © 2017 by The American Society of Hematology